Cardiometabolic & kidneyGuideline or statement
Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities
- Expert opinion
Recommendations
As issued by the authors
Choice and combination (simultaneous or sequential) of pillars guided by chronic kidney disease (CKD) grade and albuminuria, glycaemia, comorbidities (atherosclerotic CVD, HF, obesity), concomitant medications and serum potassium
Efficacy and safety profiles of each pillar from landmark trials, along with real-world data, should be carefully considered when selecting therapy
Original publication
Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities. Eur J Prev Cardiol. Published 15 July 2025. doi:10.1093/eurjpc/zwaf426
Summarised from the published abstract; every number is checked against it